How many shares of ARWR are there?
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a clinical-stage biopharmaceutical enterprise specializing in the development of novel therapies for central nervous system disorders. According to official corporate financial filings and NASDAQ market capitalization reports, the enterprise maintains an active equity structure comprising approximately 51.2 million common shares outstanding. This share count shifts periodically based on secondary public offerings, warrant conversions, and employee stock option exercises.
Related FAQs
Cohen & Steers, Inc. is a prominent specialized global investment management firm recognized as an industry leader in real estate securities, real assets, and alternative income strategies.
Astronics Corporation is a leading global supplier of advanced technologies, lighting, electrical power systems, and avionics structures for the aerospace, defense, and semiconductor industries.
Evaluating the share price volatility of Eagers Automotive—traded on the Australian Securities Exchange under the ticker APE—reveals a moderate to high volatility profile characteristic of consumer discretionary retail and automotive dealership gr...
Evaluating Arrowhead Pharmaceuticals (ticker ARWR) as an equity investment requires analyzing its innovative RNA interference therapeutic pipeline, clinical trial milestones, and major pharmaceutical partnership agreements.
Determining if Arrowhead Pharmaceuticals represents a compelling long-term stock involves assessing its scientific leadership in gene silencing technologies and its ability to commercialize breakthrough RNAi therapeutics.
Arrowhead Pharmaceuticals operates within strict bioethical and regulatory compliance standards established by international health authorities, institutional review boards, and government regulatory agencies for clinical drug development.